1Cundiff DK. Clinical evidence for rebound hypercoagulability after discontinuing oral anticoagulants for venous thromboembolism [ J ]. Medscape J Med, 2008, 10( 11 ) : 258 -264.
2Albers GW, Amarenco P, Easton JD, et al. Antithrombotic and thrombolytic therapy for ischemic stroke : american college of chest physicians evidence-based clinical practice guidelines [ J ]. Chest, 2008, 133(6 suppl) : 630 -639.
3Blankenship JC. Bleeding complications of glycoprotein IIb/111 a receptor inhibilors. Am Heart J, 1999,138:287-296.
4Michael A,James A,Harvey D,et al. Safety and efficacy of enox- aparin vs unfractionated heparin in patients With Non - ST-seg- ment elevation acute coronary syndromes who receive tirofiban and aspirin. JAMA ,2004,292:55-64.
5Leger A J,Jacques SL,Badar J,et al.Blocking the protease-activated receptor 1-4 heterodimer in platelet-mediated thrombosis.Circulation,2006,113:1244-1254.
6Mosnier LO,Sinha RK,Bumier L,et al.Biased agonism of protease-activated receptor 1 by activated protein C caused by noncanonical cleavage at Arg46.Blood,2012,120:5237-5246.
7Caron MF,Mckendall GR.Bivalirudin in percutaneous coronary intervention.Am J Health Syst Pharm,2003,60:1841-1849.
8Bittl JA,Chaitman BR,Feit F,et al.Bivalirudin versus heparin during coronary angioplasty for unstable or postinfarction angina:final report reanalysis of the Bivalirudin ^ ngioplasty study.Am Heart J,2001,142:952-959.
9Lincoff AM,Bittl JA,Harrington RA,et al.Bivalirudin and provisional glycoprotein Ⅱ b /Ⅲ a blockade compared with heparin and planned glycoprotein Ⅱ b / Ⅲ a blockade during percutaneous coronary intervention:REPLACE-2 randomized trial.JAMA,2003,289:853-863.
10Rajagopal V,LincoffAM,Cohen D J,et al.Outcomes of patients with acute coronary syndrome who are treated with bivalriudin during percutaneous coronary intervention:an analysis from the Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events (REPLACE-2) trail.Am Heart J,2006,152:149-154.
